long term effects of glp-1 agonists GI Adverse Glucagon-Like Peptide-1 Receptor GLP-1 Receptor Agonists | New

Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial

Common side effects include nausea, vomiting, diarrhoea, abdominal pain, and reduced appetite, especially when starting or increasing the dose

In clinical trials targeting obese populations, Survodutide demonstrated varying degrees of weight loss across dosages ranging from 0.6 to 4.8 milligrams

Researchers have shown that the number of quit attempts needed during recovery varies by substance and individual circumstances

Important toxicologic components include serotonin, amine oxidase, phospholipase A, substances promoting the release of bradykinin, helodermin, hyaluronidase, and exendin 4

In STEP-4 (NCT03548987), maintenance semaglutide after 20 weeks for another 48 weeks led to a further 7.9% bodyweight loss for a total 17.4% weight loss over the whole trial, whereas those who switched to placebo regained an average 6.9% (total weight loss of 5.0%) [66]